
|Articles|March 15, 2004
FDA extends review of Vitrase by 90 days
Irvine, CA-The FDA is extending its review of ISTA Pharmaceuticals Inc.'s new drug application for Vitrase for use as a spreading agent by 90 days to allow for a full review.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA grants IDE approval to EyeYon Medical for its US clinical study of EndoArt
2
Ocular Therapeutix accelerates NDA submission plans for AXPAXLI for wet AMD
3
First patient treated in ViaLase’s IDE trial
4
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
5















































.png)


